| Cytotoxic effect of progesterone, tamoxifen and their combination in experimental cell models of human adrenocortical cancer E Rossini, M Tamburello, A Abate, S Beretta, M Fragni, M Cominelli, ... Frontiers in Endocrinology 12, 669426, 2021 | 18 | 2021 |
| An update on adrenocortical cell lines of human origin S Sigala, E Rossini, A Abate, M Tamburello, SR Bornstein, C Hantel Endocrine 77 (3), 432-437, 2022 | 15 | 2022 |
| Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? V Cremaschi, A Abate, D Cosentini, S Grisanti, E Rossini, M Laganà, ... Expert Opinion on Pharmacotherapy 23 (12), 1413-1424, 2022 | 13 | 2022 |
| Estrogen-like effect of mitotane explained by its agonist activity on estrogen receptor-α E Rossini, E Giacopuzzi, F Gangemi, M Tamburello, D Cosentini, A Abate, ... Biomedicines 9 (6), 681, 2021 | 13 | 2021 |
| Ribociclib cytotoxicity alone or combined with progesterone and/or mitotane in in vitro adrenocortical carcinoma cells A Abate, E Rossini, M Tamburello, M Laganà, D Cosentini, S Grisanti, ... Endocrinology 163 (2), bqab248, 2022 | 11 | 2022 |
| FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma M Tamburello, B Altieri, I Sbiera, S Sigala, A Berruti, M Fassnacht, ... Endocrine 77 (3), 411-418, 2022 | 8 | 2022 |
| Erythropoiesis in Cushing syndrome: sex-related and subtype-specific differences. Results from a monocentric study M Detomas, T Deutschbein, M Tamburello, I Chifu, O Kimpel, S Sbiera, ... Journal of Endocrinological Investigation 47 (1), 101-113, 2024 | 6 | 2024 |
| Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models A Abate, M Tamburello, E Rossini, RM Basnet, G Ribaudo, A Gianoncelli, ... Endocrine-Related Cancer 30 (2), 2023 | 6 | 2023 |
| Preclinical evidence of progesterone as a new pharmacological strategy in human adrenocortical carcinoma cell lines M Tamburello, A Abate, E Rossini, RM Basnet, D Zizioli, D Cosentini, ... International Journal of Molecular Sciences 24 (7), 6829, 2023 | 5 | 2023 |
| FSCN1 as a new druggable target in adrenocortical carcinoma C Ruggiero, M Tamburello, E Rossini, S Zini, N Durand, G Cantini, ... International Journal of Cancer 153 (1), 210-223, 2023 | 4 | 2023 |
| Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable … A Turla, M Laganà, A Abate, V Cremaschi, M Zamparini, M Chittò, ... Cancers 15 (18), 4491, 2023 | 3 | 2023 |
| Retrospective Analysis of Patient-Reported Adverse Drug Reactions in an Italian Allergy Unit: ALLERG-RAF Study A Abate, E Rossini, M Tamburello, D Paganotti, M Cinquini, S Sigala, ... Pharmacology 109 (3), 129-137, 2024 | | 2024 |
| 36P Progesterone and trabectedin activity in preclinical cell models of adrenocortical carcinoma A Abate, M Tamburello, RM Basnet, D Zizioli, M Laganà, D Cosentini, ... ESMO Open 9, 2024 | | 2024 |
| 37P Estrogen-mimetic effects of mitotane in patients with adrenocortical carcinoma: Focus on this neglected toxicity A Turla, M Laganà, V Cremaschi, B Trevisan, A Abate, M Tamburello, ... ESMO Open 9, 2024 | | 2024 |
| The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study E Rossini, M Tamburello, A Abate, S Zini, G Ribaudo, A Gianoncelli, ... Cells 13 (5), 368, 2024 | | 2024 |
| Outcome of brain metastases from adrenocortical carcinoma: a pooled analysis A Turla, M Laganà, V Cremaschi, M Zamparini, L De Maria, F Consoli, ... Journal of Endocrinological Investigation 47 (1), 223-234, 2024 | | 2024 |
| PPARG dysregulation as a potential molecular target in adrenal Cushing's syndrome S Vetrivel, M Tamburello, A Oßwald, R Zhang, A Khan, S Jung, JE Baker, ... Frontiers in Endocrinology 14, 1265794, 2023 | | 2023 |
| FGF/FGFR signaling in adrenocortical tumorigenesis: Novel potential therapeutic targets in adrenocortical carcinoma L Kappenstein, A Paul, B Altieri, I Sbiera, S Sandra, B Alfredo, ... Endocrine Abstracts 93, 2023 | | 2023 |
| Preclinical and clinical evidence of progesterone/megestrol acetate activity in metastatic adrenocortical carcinoma M Tamburello, A Abate, A Turla, M Lagana, E Rossini, C Hantel, ... Endocrine Abstracts 93, 2023 | | 2023 |
| WEE1 kinase inhibitor, adavosertib (AZD1775), as a novel potential therapeutic strategy in advanced adrenocortical carcinoma M Tamburello, S Sbiera, W Justus, J Lippert, M Detomas, MP Schauer, ... Endocrine Abstracts 90, 2023 | | 2023 |
